Subscribe to Search results

Dr Kernoff suggested that cryoprecipitate, although relatively cheap to produce, had serious clinical disadvantages and that the shortfall in NHS concentrates had to be met by buying commercial concentrate.

Published on:

In his letter to Dr Colvin, Dr Kernoff described NANBH as a serious disease with long-term consequences.

Published on:

In his letter to Mr Jones, Dr Kernoff referred to the Royal Free policy to attempt to maintain individual patients on particular brands to minimise the risk of hepatitis.

Published on:

The NANBH risks associated with Factor 8 concentrates were the subject of discussion at the Haemophilia Working Party's meeting.

Published on:

At the meeting of the Haemophilia Working Party, it was agreed that all registered haemophiliacs on regular treatment should be fully screened for hepatitis at their regular three-month visits to the major haemophilia centres.

Published on:

Dr Kernoff stated 25% of all Factor VIII used was in the form of cryoprecipitate which was unsatisfactory at the Royal Free Hospital.

Published on:

A clinical study done by Dr Dormandy with the US counterparts demonstrated that haemophiliacs treated exclusively with the new concentrates suffered raised transaminases more commonly than UK patients who were treated with cryoprecipitate.

Published on:

Dr Kernoff agreed with Dr Dormany that factor concentrates exposed recipients to a greater risk of infection because of the large sizes of the pools from which they were made.

Published on:

Dr Craske published an article titled 'An outbreak of hepatitis associated with intravenous injection of Factor VIII concentrate' in The Lancet

Published on:

Dr Biggs served as director of the Oxford Reference Centre until 1977 when she was succeeded by Dr Rizza.

Published on:

Due to the co-location and cooperation of the PFL and Oxford Haemophilia Centre, it made the switch from cryoprecipitate to factor concentrates relatively early.

Published on:

Between 1969 to 1974, cryoprecipitate use at the Oxford Haemophilia Centre dropped from 21.99% to 3.86% of total Factor 8 material used, while the use of NHS concentrate rose from 45.93% to 60.89% of the total.

Published on:

By 1975 there was only about 25% of Haemophilia A patients using home therapy.

Published on:

In 1977, Dr Bidwell said Factor 9 requirements had increased substantially. It did not allow for prophylactic treatment except for occasional short periods. But prophylaxis for severely affected patients was allowed where no substantial increase in usage occurred.

Published on:

By 1976, 42.6% of the material used at Oxford Haemophilia Centre was NHS Factor 8 concentrate, just 1.54% was cryoprecipitate, and the rest was commercial concentrate (Hyland & Immuno).

Published on:

Following an increase in plasma supplied, nearly double, the Oxford Centre was able to transfer several patients from commercial to NHS concentrate.

Published on:

The Oxford Haemophilia Centre used Profilate and Koate. Dr Rizza described them all as equally effective clinically and they usually use Hemofil.

Published on:

NHS Factor 8 was always in very short supply and reserved as far as possible for young children and adolescents. Dr Rizza wrote that most severely affected patients had changed from NHS to commercial factor VIII, especially those who use larger amounts of factor VIII.

Published on:

A report produced by Dr Rizza held demonstrated how the view of the impact of hepatitis on haemophiliacs changed from the early to late 1970s and how by the late 1970s there were a significant number of people who had significant number with abnormal liver histology consistent with chronic liver disease.

Published on:

A study by J Spero reported persistent abnormalities in liver-function for haemophiliac patients. A significant number demonstrated results of anti-HBc (56 of 65, or 86 percent). Many showed signs of chronic liver disease.

Published on: